



Harmony P Garges, MD MPH



- / **Chief Medical Officer and Head of Global Medical for ViiV Healthcare**, the only pharmaceutical company 100% focused on HIV.
- / Accountable for all aspects of human safety and medical governance for the company and leads the medical affairs, pharmacovigilance and regulatory functions
- / Physician with 20+ year expertise in **pediatrics and infectious diseases**
- / 15+ years of experience within the pharmaceutical industry with leadership experience across **R&D, pharmacovigilance, and medical affairs**



—

ViiV Healthcare:

On a global pursuit to
leave no person living
with HIV behind

—

Dr Harmony P Garges
Chief Medical Officer
2 December 2021


Our commitment to ESG



Environmental



Social







Governance



Warren
Living with HIV
Alabama, US

Decades of progress have changed the HIV epidemic



But the HIV epidemic is not over

37.9 million people are eligible for antiretroviral therapy

Under the 'Treat All' approach advocated by WHO's guidelines^{1,2}

Continued HIV transmission

1.5 million new cases each year³

COVID-19 impacting progress

significant reduction in HIV testing and switch through the pandemic³

Access to treatment is crucial

But only ~73% of all PLHIV⁴ are accessing treatment³

Pre-exposure prophylaxis (PrEP) is underutilised

even in developed countries like the US, where only 25% of those who could benefit from PrEP are taking it⁵

Need for new approaches in treatment

One in three are not virally suppressed³




HIV treatment and prevention are about more than medicine



Improving health disparities



Clinical Trial Diversity Task Force



The report:



Provides the clear case for why action is needed



Identifies stakeholders who can combat disparities



Brings forth the actions that can be taken to address disparities

POSITIVE ACTION



Reframing Risk Black Women's Working Group



ViiV Healthcare – focused on ending HIV and AIDS



Our mission is to leave no person living with HIV behind.



Leaders and disruptors in innovation



Focused and agile, backed by scale of GSK



Built on novel collaborations and powerful partnerships



Strong commitment to communities

2009	2012	2013	2016	2019	2020	2021
GSK and Pfizer ¹ created a joint venture dedicated to HIV	Shionogi ² became partner and shareholder	First dolutegravir launch in the US	Acquired BMS ³ HIV pipeline and discovery assets	Launched <i>Dovato</i>	Launched <i>Rukobia</i> , first attachment inhibitor	Launched <i>Cabenuva</i> , first long-acting injectable. Strengthened pipeline with Halozyme ⁴ and Shionogi collaborations

1. Pfizer Inc. 2. Shionogi & Company 3. Bristol-Myers Squibb Company 4. Halozyme, Inc.

Our commitment to paediatrics

Through our scientific research, innovative partnerships and local community work, we are addressing gaps in paediatric HIV treatment and accelerating access to medicines for infants and children around the world.



1.7 million


Children under 15 years of age are living with HIV



Every 100 seconds

A child or young person under the age of 20 is newly infected with HIV

Our commitment to access



Making our medicines as widely available to patients regardless of income or where they live



Taking an innovative, responsible and, above all, sustainable approach

Access and care to all and each PLHIV



Alignment with the global HIV response and agenda set by UNAIDS and the Sustainable Development Goals (SDGs)

Our commitment to community

100+ projects selected for ViiV COVID-19 Emergency Response Fund



Eddie
Living with HIV
Florida, US



—
**To leave no person
living with HIV
behind**

Visit [ViiVHealthcare.com](https://www.viiVhealthcare.com)
to learn more

Yulia,
Living with HIV,
St Petersburg, Russia

